MGNX - MacroGenics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

MacroGenics, Inc.

9704 Medical Center Drive
Rockville, MD 20850
United States
301-251-5172
http://www.macrogenics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees364

Key Executives

NameTitlePayExercisedYear Born
Dr. Scott KoenigCEO, Pres & Director916.17k635.2k1952
Mr. James KarrelsSr. VP, CFO & Sec.546.76k230.72k1967
Dr. Ezio BonviniSr. VP of Research & Chief Scientific Officer593.39kN/A1954
Mr. Eric Blasius RisserSr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer550.2k453.39k1973
Dr. Jon M. WiggintonSr. VP of Clinical Devel. & Chief Medical Officer641.58k77.49k1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Corporate Governance

MacroGenics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.